Ipamorelin vs MK-677: Injected Peptide vs Oral Ghrelin Mimetic

Why this comparison exists

People searching "MK-677 vs ipamorelin" are usually deciding between two ways of pushing the same lever. Both compounds act on the growth hormone secretagogue receptor, the receptor ghrelin uses, and both make the pituitary release more growth hormone. The differences are in what they are made of, how they get into the body, how long they act, and how much is known.

This page is written from ipamorelin's side. MK-677 is not a peptide, and this site covers it only as a comparator to the GH peptides; the details of its trials are on the MK-677 page.

Side by side

What ipamorelin's record actually contains

Ipamorelin's reputation rests on a 1998 animal paper. In pigs it released GH about as well as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol, even at doses more than 200 times the amount needed for GH release. That is the origin of "clean GH release".

Its two human studies are narrow:

• Gobburu and colleagues (1999) infused it into healthy men, eight per dose level across five doses. Every dose produced a single GH pulse peaking at about 40 minutes; the terminal half-life was about two hours. That is a pharmacokinetic study, not an outcome study.
• Beck and colleagues (2014) tested whether ghrelin receptor stimulation would speed gut recovery after bowel surgery. In 114 analysed patients, twice-daily IV ipamorelin for up to a week did not shorten time to a tolerated meal compared with placebo. Development stopped.

So the ipamorelin record contains no measurement of lean mass, fat, IGF-1 over weeks, glucose, sleep or cortisol in a person. Those are precisely the things people are choosing it for, and every claim about them is inferred from the pig data or from the wider GH-secretagogue class.

What MK-677 has that ipamorelin lacks

The key document is a two-year, double-blind, placebo-controlled trial in 65 healthy adults aged 60 to 81 published in 2008. On 25 mg daily, GH and IGF-1 rose to young-adult levels, fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, and body weight rose 2.7 kg against 0.8 kg. Visceral fat did not change. The extra lean mass did not translate into strength or function. Fasting glucose rose by an average of 0.3 mmol/L, insulin sensitivity fell, cortisol rose, and the most common side effects were appetite, mild leg swelling and muscle pain.

A separate trial in 123 older adults recovering from hip fracture was stopped early because of a congestive heart failure signal, and the US FDA lists ibutamoren on its compounding safety-risk list on that basis.

That is a real evidence base with real findings, some favourable and some not. The point for this comparison is that the unfavourable findings, glucose and cortisol and heart failure in a frail population, were only discovered because the trial existed. Ipamorelin has not been through the equivalent test.

Reading the two together

Three observations follow from putting the records side by side.

1. Pulse versus plateau is a real pharmacological difference. Ipamorelin's GH signal is over within hours; MK-677 with daily dosing keeps GH and IGF-1 raised continuously. Whether a pulse is safer or merely shorter has not been tested, but the two are not the same exposure.
2. The cortisol difference is animal data on one side and human data on the other. MK-677 raised cortisol in people. Ipamorelin did not raise it in pigs. These are not comparable findings, and there is no human cortisol measurement for ipamorelin at all.
3. "Fewer reported side effects" partly means "fewer measurements". With two small studies, ipamorelin has had little chance to show a signal. The FDA's 2024 review of ipamorelin listed incomplete impurity characterisation, minimal toxicology data, a possible reinforcing effect through the ghrelin receptor, and possible effects on fertility and fetal development as open questions.

Both raise IGF-1, so both carry the theoretical concerns attached to any GH-raising compound: fluid retention, joint aches, reduced insulin sensitivity, and the unresolved relationship between IGF-1 and cancer. The side effects hub collects the GH-axis picture.

Where ipamorelin sits in its own family

Against other injectable secretagogues, ipamorelin's selling point is selectivity over the older GHRPs, covered on GHRP-2 vs GHRP-6. Against the GHRH analogues, which use a different receptor, it is a partner rather than a rival, which is why CJC-1295 + ipamorelin exists; see ipamorelin vs sermorelin. For how any of these compare with growth hormone itself, see HGH vs peptides.

Status in the Philippines

Neither is registered with FDA Philippines or approved as a medicine anywhere, and neither is a controlled substance under RA 9165. Ipamorelin is one of the most common GH peptides in the local research market, usually pre-mixed with CJC-1295. MK-677 is sold as capsules or liquid through gym and research channels. Given MK-677's glucose findings and ipamorelin's absence of any, fasting glucose, HbA1c and IGF-1 are the labs the literature points to for either; see bloodwork in the Philippines.

Storage

Ipamorelin is a freeze-dried peptide: refrigerate before mixing, keep at 2 to 8°C afterward, and plan for brownouts. The ipamorelin calculator handles reconstitution. MK-677 as a small molecule is more heat-tolerant and needs no mixing; keep it sealed, dry and out of the sun.